ImpriMed, Inc.
PrivateLast Round
Series A
Extension
Sep 18, 2026
Est. Valuation
$47.52M
Total Funding Raised
$37.03M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
ImpriMed, Inc. operates in Healthcare & Life Sciences and is based in Palo Alto, California. Its latest recorded funding round was a Series A Extension round in September 2026.
ImpriMed, Inc. is a precision medicine company that utilizes artificial intelligence and lab testing of live cancer cells to predict patient response to various cancer treatments.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Medical AI, Healthcare Analytics
Business Model
B2B
Customer Profile
Usage-Based SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImpriMed, Inc. Comparables
Compare ImpriMed, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| FidoCure | 85% | |
| VetOmics | 72% | |
| Anivive Lifesciences | 69% |
For institutional investors. Book with your work email.
ImpriMed, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Sep 18, 2026 | ||||
| Series A | Dec 19, 2023 | ||||
| VC Round | Apr 13, 2021 | ||||
| Seed | Apr 12, 2019 | ||||
| Pre Seed | Jun 1, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ImpriMed, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Draper Dragon | VC Round |
| StartX | Seed |
| NAVER D2SF | Series A Extension |
| Plug and Play Tech Center | Seed, Pre Seed |
| Han River Partners | Series A |
| Murex Partners | VC Round, Series A, Seed |
| Samsung Securities Co., Ltd. | Series A Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 18, 2026
$10M round led by LB Investment.
- Mar 4, 2026
Helped over 11,000 dogs and cats with cancer.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingSep 23, 2026
On Sep 18 '26, ImpriMed, Inc. raises a $10M Series A2 bridge for precision oncology, led by LB Investment with new investors NAVER D2SF, Samsung Securities, and Alois Ventures, alongside returning investors BonAngels and Han River Partners.
- expands_offices_toSep 18, 2026
ImpriMed, Inc. expands into Asia as it advances U.S. commercialization through its $10 million Series A2 bridge round, announced in South Korea on Sep 18th '26.
- is_developingSep 18, 2026
On Sep 18th '26, ImpriMed, Inc. is developing AI models trained on more than 3.5 million data points that combine real-world data with functional cell analysis to improve predictive accuracy.
- receives_financingSep 18, 2026
On Sep 18th '26 in South Korea, ImpriMed, Inc. receives $10M in Series A2 Bridge financing from NAVER D2SF to advance U.S. commercialization and expand into Asia.
For institutional investors. Book with your work email.
ImpriMed, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ImpriMed, Inc.'s valuation, stock price, and market status.
Is ImpriMed, Inc. a public or private company?
ImpriMed, Inc. is a private company.
What is the current stock price of ImpriMed, Inc.?
ImpriMed, Inc. is a private company, so its shares have no public market price. Caplight tracks ImpriMed, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ImpriMed, Inc. worth (valuation)?
ImpriMed, Inc.'s valuation is estimated at $47.5M based on funding round data.
Can I buy ImpriMed, Inc. stock?
ImpriMed, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ImpriMed, Inc.'s last funding round?
ImpriMed, Inc.'s most recent funding round was Series A Extension on September 18, 2026.
Who are the main investors in ImpriMed, Inc.?
Key investors in ImpriMed, Inc. include Plug and Play Tech Center, SBVA, Draper Associates, LB Investment, HG Initiative.
Will ImpriMed, Inc. IPO soon?
No public IPO plans have been announced for ImpriMed, Inc..
How can I track ImpriMed, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in ImpriMed, Inc.'s shares on secondary markets.